Johnson & Johnson
JNJ Healthcare Drug Manufacturers General
Johnson & Johnson’s revenue for fiscal 2025 (year ended December 2025) was $94.2 billion, up 6.05% from fiscal 2024. In the quarter to September 2026, revenue grew 5.86%, EPS was flat, free cash flow grew 154.8% and total debt fell 4.82%, each against the same quarter a year earlier. Member of the S&P 500 and Dow Jones; dividend growth for twenty-five consecutive years, revenue growth for three, operating cash flow growth for three; insiders bought in the last twelve months.
Follow JNJ
Johnson & Johnson (JNJ) Gross margin
Johnson & Johnson's gross margin over the twelve months to 30 September 2026 was 67.6%, down 0.3 percentage points from fiscal 2025 (67.9%). Over the past ten years it has ranged from 65.6% (fiscal 2020) to 70.3% (fiscal 2021); the current reading is higher than 45% of that period. That is below the Drug Manufacturers General industry median of 72.8% and above the Healthcare sector median of 53.5%.
Gross margin, annual
Embed this chart
Annual newest first
| Period | Gross margin | Change (points) |
|---|---|---|
| FY2025 | 67.9% | (1.19) |
| FY2024 | 69.1% | 0.25 |
| FY2023 | 68.8% | (0.43) |
| FY2022 | 69.3% | (1.03) |
| FY2021 | 70.3% | 4.70 |
| FY2020 | 65.6% | (0.84) |
| FY2019 | 66.4% | (0.37) |
| FY2018 | 66.8% | 0.07 |
| FY2017 | 66.7% | (2.97) |
| FY2016 | 69.7% | 0.42 |
Quarterly newest first
| Period | Gross margin | Change (points) |
|---|---|---|
| Sep 2026 | 68.1% | (0.07) |
| Jun 2026 | 68.2% | 1.88 |
| Mar 2026 | 66.3% | (1.25) |
| Dec 2025 | 67.6% | (2.00) |
| 43 more quarters | Free account |
Against its own ten years
Gross margin against peers
| Company | Gross margin |
|---|---|
| LLY Eli Lilly and Company compare | 83.4% |
| AZN AstraZeneca PLC compare | 81.9% |
| GILD Gilead Sciences, Inc. compare | 79.6% |
| NVS Novartis AG compare | 74.7% |
| PFE Pfizer Inc. compare | 73.2% |
| MRK Merck & Co., Inc. compare | 73.0% |
| ABBV AbbVie Inc. compare | 71.5% |
| AMGN Amgen Inc. compare | 69.5% |
| JNJ Johnson & Johnson | 67.6% |
| Drug Manufacturers General industry median | 72.8% |
| Healthcare sector median | 53.5% |
| Market median | 46.2% |
What Gross margin is
Gross Margin tells an investor how much of each sale a company keeps after paying the direct costs of making or buying what it sells.
Gross Profit ÷ Revenue
More on JNJ
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement